I SEE WALDENSTRÖM Macroglobulinemia

“I See Waldenström Macroglobulinemia” is a dedicated resource to help you find the latest information about the signs, symptoms, diagnoses and treatment of WM.

WHAT IS WALDENSTRÖM Macroglobulinemia?

Waldenström Macroglobulinemia (WM) is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells, along with IgM monoclonal gammopathy. ¹

An infographic stating that WM makes up 1–2% of non-Hodgkin lymphoma cases, 60–75 years is the median age at WM diagnosis, and WM is twice as common in men as it is in women.

Understand how WM is diagnosed

IgM=immunoglobulin M.

References:

Owen RG, et al. Clinicopathological definition of Waldenström Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström Macroglobulinemia. Semin Oncol 2003;30(2):110–15.
Leukemia & Lymphoma Society. Waldenström Macroglobulinemia facts. Available at: https://www.llscanada.org/sites/default/files/file_assets/FS20_Waldenstrom_M%20FINAL%206.15.pdf. Accessed August 24, 2021.
Anderson KC, et al. NCCN Guidelines® Insights – Waldenström’s macroglobulinemia/lymphoplasmacytic lymphoma, Version 2.2013: Featured updates to the NCCN Guidelines. JNCCN 2012;10:1211–1218. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Waldenström Macroglobulinemia/Lymphoplasmatic Lymphoma V.2.2022 – December 7, 2021. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 4, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org.
Kastritis E, et al. Competing risk survival analysis in patients with symptomatic Waldenström Macroglobulinemia: the impact of disease unrelated mortality and or rituximab-based primary therapy. Haematologica 2015;100(11):e446–9.
Teras, LR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. Ca Cancer J Clin 2016;66:443–59.
Treon SP. How I treat Waldenström Macroglobulinemia. Blood 2015;126(6):721–32.
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Waldenström Macroglobulinemia/Lymphoplasmatic Lymphoma V.2.2022 – December 7, 2021. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 4, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.